1[1]Baigent C,Keech A,Kearney PM,et al.Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins[J].Lancet,2005,366:1267-1278.
2[2]Amarenco P,Labreuche J,Lavallee P,et al.Statins in stroke prevention and carotid atherosclerosis:systematic review and up-to-date meta-analysis[J].Stroke,2004,35:2902-2909.
3[3]LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J].N Engl J Med,2005,352:1425-1435.
4[4]Wiviott SD,Cannon CP,Morrow DA,et al.Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy:a PROVE IT-TIMI 22substudy[J].J Am Coll Cardiol,2005,46:1411-1416.
5[5]Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomised placebo-controlled trial[J].Lancet,2002,360:7-22.
6[6]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial[J].JAMA,2001,285:1711-1718.
7[7]Newman C,Tsai J,Szarek M,et al.Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236patients[J].Am J Cardiol,2006,97:61-67.
8[8]Amarenco P,Bogousslavsky J,Callahan A 3rd,et al.High-dose atorvastatin after stroke or transient ischemic attack[J].N Engl J Med,2006,355:549-559.
9[9]Guyton JR.Benefit versus risk in statin treatment[J].Am J Cardiol,2006,97:95C-97C.
10[10]Gotto AM Jr.Statins,cardiovascular disease,and drug safety[J].Am J Cardiol,2006,97:3C-5C.
5McMurray J J V,Kjekshus J,Gullestad L,et al. Effects of statin therapy according to plasma high-sensitivity C-reac- tive protein concentration in the controlled rosuvastatin multinational trial in heart failure (CORONA).A retrospec- tive analysis[ J ]. Circulation, 2009 (120) : 2188-2194.
6Chou T C,Lin Y F,Wu W C,et al. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin[J]. BrJ Pharmacol,2008,153(6): 1281-1287.
7Undas A,Brummel K E,Musial J,et al. Simvastatin depressesblood clotting by inhibiting activation of prothrombin,factor V, and factor X II and by enhancing factor Va inactivation [ J ]. Circulation, 2001 ( 103 ) : 2248 - 2253.
8LaRosa J C,Grundy S M,Waters D D,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J]. N Engl J Med,2005,352( 14): 1425-1435.
9Ebrahim S,Sung J,Song Y M,et al. Serum cholesterol, haemorrhagic and ischemic stroke and myocardial infarction: Korean national health service prospective cohort study[J] BMJ,2005(333) :22.
10Amarenco P, Labreuehe J, Lavallee P, et al. Statin in stroke prevention and carotid atheroselerosis:systematie review and met.a-analysis[ J ]. Stroke, 2004(35 ) : 2902-2909.
